These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 24497006)
21. The Impact of Varenicline on Alcohol Consumption in Subjects With Alcohol Use Disorders: Systematic Review and Meta-Analyses. Gandhi KD; Mansukhani MP; Karpyak VM; Schneekloth TD; Wang Z; Kolla BP J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32097546 [TBL] [Abstract][Full Text] [Related]
22. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818 [TBL] [Abstract][Full Text] [Related]
23. Medications development to treat alcohol dependence: a vision for the next decade. Litten RZ; Egli M; Heilig M; Cui C; Fertig JB; Ryan ML; Falk DE; Moss H; Huebner R; Noronha A Addict Biol; 2012 May; 17(3):513-27. PubMed ID: 22458728 [TBL] [Abstract][Full Text] [Related]
24. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Johnson BA; Swift RM; Ait-Daoud N; DiClemente CC; Javors MA; Malcolm RJ Alcohol Clin Exp Res; 2004 Feb; 28(2):295-301. PubMed ID: 15112937 [TBL] [Abstract][Full Text] [Related]
25. Predictive value of non-consumption outcome measures in alcohol use disorder treatment. Kirouac M; Witkiewitz K Addiction; 2019 Jun; 114(6):1086-1092. PubMed ID: 30650471 [TBL] [Abstract][Full Text] [Related]
26. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Hauser P; Fuller B; Ho SB; Thuras P; Kern S; Dieperink E Addiction; 2017 Jul; 112(7):1173-1183. PubMed ID: 28192622 [TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy of alcoholism - an update on approved and off-label medications. Soyka M; Müller CA Expert Opin Pharmacother; 2017 Aug; 18(12):1187-1199. PubMed ID: 28658981 [TBL] [Abstract][Full Text] [Related]
28. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder. Brown ES; Van Enkevort E; Kulikova A; Escalante C; Nakamura A; Ivleva EI; Holmes T Alcohol Clin Exp Res; 2019 Feb; 43(2):317-323. PubMed ID: 30457668 [TBL] [Abstract][Full Text] [Related]
29. Medications for alcohol use disorders: An overview. Akbar M; Egli M; Cho YE; Song BJ; Noronha A Pharmacol Ther; 2018 May; 185():64-85. PubMed ID: 29191394 [TBL] [Abstract][Full Text] [Related]
30. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Umhau JC; Schwandt ML; Usala J; Geyer C; Singley E; George DT; Heilig M Neuropsychopharmacology; 2011 May; 36(6):1178-86. PubMed ID: 21289601 [TBL] [Abstract][Full Text] [Related]
31. Thirty- Versus Ten-Day Diazepam Treatment for Alcohol Detoxification and a Comparison of Drinking Patterns, Craving, and Anxiety for up to 12 Weeks: A "Proof-of-Concept" Open-Label Randomized Controlled Trial. Simioni N; Labreuche J; Behal H; Cottencin O; Rolland B J Clin Psychopharmacol; 2017 Dec; 37(6):722-728. PubMed ID: 28984747 [TBL] [Abstract][Full Text] [Related]
34. Effects of D-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. Kiefer F; Kirsch M; Bach P; Hoffmann S; Reinhard I; Jorde A; von der Goltz C; Spanagel R; Mann K; Loeber S; Vollstädt-Klein S Psychopharmacology (Berl); 2015 Jul; 232(13):2353-62. PubMed ID: 25697860 [TBL] [Abstract][Full Text] [Related]
35. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ; Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402 [TBL] [Abstract][Full Text] [Related]
36. The role of psychosocial treatments in pharmacotherapy for alcoholism. McCaul ME; Petry NM Am J Addict; 2003; 12(s1):s41-s52. PubMed ID: 14972779 [TBL] [Abstract][Full Text] [Related]
37. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Addolorato G; Caputo F; Capristo E; Domenicali M; Bernardi M; Janiri L; Agabio R; Colombo G; Gessa GL; Gasbarrini G Alcohol Alcohol; 2002; 37(5):504-8. PubMed ID: 12217947 [TBL] [Abstract][Full Text] [Related]
38. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866 [TBL] [Abstract][Full Text] [Related]
39. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A; JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409 [TBL] [Abstract][Full Text] [Related]